Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 283 • 2019 ACR/ARP Annual Meeting
Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD
Lene Terslev¹, Mikkel Østergaard ², Joe Sexton ³ and Hilde Hammer ⁴, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁴Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: Ultrasound is used to assess disease activity in rheumatoid arthritis (RA). Gray scale (GS) ultrasound shows the synovial hypertrophy (SH) and Doppler the amount…
Abstract Number: 448 • 2019 ACR/ARP Annual Meeting
Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory
Kentaro Noda¹, Moe Saitou ¹, Taro Ukichi ¹, Yohsuke Oto ¹, Ken Yoshida ¹ and Daitaro Kurosaka ¹, ¹The Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: Pain of rheumatoid arthritis (RA) is thought to be nociceptive. However, recent studies indicate that RA pain also includes the mechanism of central sensitization…
Abstract Number: 474 • 2019 ACR/ARP Annual Meeting
Associations of Plasma Extravesicular (EV) MicroRNA Levels in Seropositive and Seronegative Rheumatoid Arthritis (RA)
Lissette Delgado-Cruzata ¹, Milena Rodriguez Alvarez ², Nickolas Almodovar³, Toni-Ann Bravo ³ and Shante Hinson ⁴, ¹John Jay College of Criminal Justice, City University of New York, New York, ²SUNY Downstate Medical Center, New York, NY, ³John Jay College of Criminal Justice, City University of New York, New York, NY, ⁴Lincoln Medical & Mental Mental Health Center, New York
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) are biomarkers that allow early diagnosis of RA in seropositive (ACPA+ or RF+) patients. However, some…
Abstract Number: 525 • 2019 ACR/ARP Annual Meeting
Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis
Larissa Valor¹, Melanie Hagen ², Michaela Reiser ³, Fabian Hartmann ³, Arnd Kleyer ², Bernhard Manger ⁴, Georg Schett ⁵, Jürgen Rech ⁶ and Koray Tascilar ⁷, ¹Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁵Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany
Background/Purpose: Persistent drug-free remission of RA is a condition close to “cure” of the disease. Long-term drug-free remission is considered rare and challenging to reach,…
Abstract Number: 820 • 2019 ACR/ARP Annual Meeting
Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis
Louise Bennett¹, Fraser Morton ¹, George Fragoulis ¹, Caron Paterson ¹, Dominic Rimmer ², Gary Semple ³, Alison Young ³, Jagtar S Nijjar ⁴, Michael Barrett ⁵, Stefan Siebert ¹, Duncan Porter ⁵, Carl Goodyear ⁶ and Iain McInnes ¹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Clinical Research Facility, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ³Clinical Research Facility, NHS Greater Glasgow and Clyde, Glasgow, ⁴Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Our understanding of disease pathogenesis in Rheumatoid Arthritis (RA) is rapidly expanding with the advent of ‘Omics’ techniques. Importantly, current analysis takes into account…
Abstract Number: 927 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
Rene Westhovens¹, William F.C. Rigby ², Désirée van der Heijde ³, Daniel W.T. Ching ⁴, Beatrix Bartok ⁵, Franziska Matzkies ⁵, Zhaoyu Yin ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Osvaldo Daniel Messina ⁷, Robert B.M. Landewé ⁸, Tatsuya Atsumi ⁹ and Gerd Burmester ¹⁰, ¹University Hospitals, Leuven, Belgium, ²Dartmouth College, Lebanon, NH, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Timaru Hospital, Timaru, New Zealand, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Cosme Argerich Hospital and IRO Medical Center, Buenos Aires, Argentina, ⁸Amsterdam University Medical Center, Amsterdam, Netherlands, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL), an orally administered, potent, selective inhibitor of Janus kinase 1 (JAK1), has shown good efficacy and was well tolerated for treatment of…
Abstract Number: 1135 • 2019 ACR/ARP Annual Meeting
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Elena Myasoedova¹, Cynthia Crowson ², Rachel Giblon ¹, Kathleen McCarthy-Fruin ¹, Daniel Schaffer ¹, Kerry Wright ¹, Eric Matteson ³ and John Davis ¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: Flares in rheumatoid arthritis (RA) are common. The shortage of readily available specialized care may hinder early detection and timely management of RA flares.…
Abstract Number: 1336 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis
Daniel Aletaha¹, Ruta Sawant ², Patrick Zueger ³, Erin Cook ⁴, Fan Mu ⁴, Vishvas Garg ² and Keith A. Betts ⁴, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs have demonstrated efficacy for the treatment of rheumatoid arthritis (RA) in clinical trials; however, real-world evidence on…
Abstract Number: 1364 • 2019 ACR/ARP Annual Meeting
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Yael Ross¹, Madhavi Siddhanthi ², Lewis VanBrackle ³, David Carpenter ⁴, Aishwarya Rallabhandy ⁵ and Mohammad Kamran ², ¹WellStar Kennestone regional medical center, Atlanta, GA, ²WellStar Medical Group, Marietta, GA, ³Kennesaw State University, Kennesaw, ⁴WellStar Kennestone regional medical center, Marietta, ⁵High School, Marietta
Background/Purpose: The goal for treatment of RA is to obtain low disease activity for better outcomes. In order to achieve low disease activity, it is…
Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Vivian Bykerk¹, Wenhui Wei ², Susan Boklage ², Toshio Kimura ², Stefano Fiore ³ and Gregory St John ⁴, ¹Hospital for Special Surgery, New York City, NY, ²Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
Abstract Number: 1428 • 2019 ACR/ARP Annual Meeting
Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta ², Xiuying Li ², Edward Keystone ¹, Claire Bombardier ² and And Other OBRI Investigators ², ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug which can be used as an alternative to biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid…
Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Kenneth Saag¹, Michele McDermott ², Jonathan Adachi ³, Willem Lems ⁴, Nancy Lane ⁵, Piet Geusens ⁶, Peter Butler ², Li Chen ², Daria Crittenden ², Robin Dore ⁷ and Stanley Cohen ⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴VU University Medical Centre, Amsterdam, Netherlands, ⁵University of California at Davis Medical Center, Sacramento, CA, ⁶Maastricht University, Maastricht, Netherlands, ⁷Robin K Dore Inc, Tustin, CA, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…
Abstract Number: 1960 • 2019 ACR/ARP Annual Meeting
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Vivian Kawai¹, Mingjian Shi ¹, Qiping Feng ², Cecilia Chung ¹, Ge Liu ², Nancy Cox ², Dan Roden ², C. Michael Stein ¹ and Jonathan Mosley ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is associated with increased risk of cardiovascular disease, cardiometabolic disorders, and autoimmune disease. Thus, we…
Abstract Number: 2096 • 2019 ACR/ARP Annual Meeting
An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients
Valeria Valerio¹, Maria Bazan ¹, Mianbo Wang ², Bruce Mazer ¹, Elizabeth M. Hazel ³, Christian Pineau ⁴, Sasha Bernatsky ⁵, Brian Ward ⁶ and Ines Colmegna ⁶, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University Health Center, Montreal, Canada, ⁶McGill University Health Center, Montreal, QC, Canada
Background/Purpose: Annual vaccination with inactivated influenza vaccine is recommended for adults with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Despite this, influenza immunization coverage…
Abstract Number: 2261 • 2019 ACR/ARP Annual Meeting
Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis
Marisel Vanesa Bejarano¹, Anastasia Secco ², Marta mamani ², Felix Romanini ² and Natalia Tamborenea ³, ¹Hospital Bernardino Rivadavia, Caba, Buenos Aires, Argentina, ²Hospital Rivadavia, Caba, Buenos Aires, Argentina, ³Hospital Rivadavia, Buenos Aires, Buenos Aires, Argentina
Background/Purpose: There is growing evidence that complex interactions between individual's genetic susceptibility, immunological processes, and environmental factors such as stress , increase the risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].